Expert Opinion on Orphan Drugs

Expert Opinion on Orphan Drugs is published by Taylor and Francis Ltd.. By OpenAlex counts of its recent articles, its largest topics are Lysosomal Storage Disorders Research, Metabolism and Genetic Disorders and Pharmaceutical Economics and Policy, together about 26.8% of its articles. Its main subfields are Genetics. (generated from OpenAlex topic counts and CAS ranking data)

This title has ceased (2024). Expert Opinion on Orphan Drugs [e-ISSN 2167-8707] is an international journal publishing rigorously peer-reviewed review articles and original papers on rare diseases and orphan drugs. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. Expert Opinion on Orphan Drugs aims to draw a spotlight on diseases that do not have a high prevalence but have a huge impact on patients and their clinicians, through valuable and high-quality expert insights. In a field which is ever-growing and changing, Expert Opinion on Orphan Drugs is committed to acting as a reliable beacon of guidance and support for researchers, clinicians, patients and advocacy groups in order to optimise research, development, management and quality of life of rare disease patients. Articles focus on the following key areas: Diagnostics, pharmacogenomics and screening; Public health and epidemiology; Drug development; Lead generation and discovery; Early or late phase clinical trials; Regulatory issues; Post-marketing safety and treatment outcomes. The journal also welcomes solicited and unsolicited papers including Drug Evaluations, specifically reviewing the pharmacological properties, clinical potential/clinical efficacy, safety and, if applicable, HE/OR data on a particular orphan drug, as well as Original Research papers and Editorials. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. *Please note that Expert Opinion on Orphan Drugs converted to a full Open Access journal from Volume 11 (2023). Previous volumes will continue to provide access through a Pay to Read model. From 2023 the Print ISSN is not in active use as this journal is no longer published in print. Sorry, there are currently no metrics available for this journal.

From the journal's Aims & Scope

Research area (LetPub): PHARMACOLOGY & PHARMACY

CAS Journal Ranking

CiteScore quartiles (Scopus, June 2026 release)

Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub

Database indexing

ScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

5.13LetPub · 2026-11-01

CiteScore 2026-06

2.3LetPub · 2026-11-01

SJR 2026-06

0.2LetPub · 2026-11-01

SNIP 2026-06

0.29LetPub · 2026-11-01

h-index

13LetPub · 2026-11-01

h-index

34OpenAlex · 2026-11-01

i10-index

144OpenAlex · 2026-11-01

2-year mean citedness

15.4OpenAlex · 2026-11-01

Share of gold OA articles

30.77%LetPub · 2026-11-01

Volume

Articles per year

3LetPub · 2026-11-01

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Taylor and Francis Ltd.

Country or region

ENGLAND

Language

English

ISSN

2167-8707

Latest issue on the website

Volume 12, Issue 1 (2024)

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗LetPub
• Special issues ↗Publisher website